This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the potential of Centanafadine, a medication currently in development by Otsuka that has recently succeeded in registrational trials with children and teens for the treatment of ADHD
Ticker(s): OTSKYWho's the expert?
Institution: Northwell Health
- Chief of the Division of Developmental and Behavioral Pediatrics at Cohen Children's Medical Center of New York (formerly Schneider Children's Hospital) and is a Professor of Pediatrics at the Zucker School of Medicine at Hofstra/Northwell in New York.
- nationally recognized as an expert in the evaluation and management of developmental and behavioral problems in children and has authored numerous research and review articles on the diagnosis and treatment of ADHD in children and adolescents.
- His academic focus and clinical experience combine to provide him with important and insightful perspectives regarding current and soon-to-be available ADHD medications from both a clinical and competitive advantage market standpoint.
In the past, he has been involved in several clinical research trials of
new medications for treatment of ADHD and other psychiatric conditions. In addition to authoring several review and research articles related to medication management of ADHD, Dr. Adesman is also the creator and author of the ADHD Medication Guide and more than 35 years of clinical experience in the evaluation and management of ADHD, and he has repeatedly been recognized by Castle Connolly as a Best Doctor in America in his field.
Interview GoalThis call will focus on the results rom the the registrational trials with children and teens for the treatment of ADHD with Centanafadine, a medication currently in development by Otsuka.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
